1f495c8c84f71b267c0a447a3e4b896d

Jay Dela Cruz, Ph.D.

President and Scientific Director - InTouch BioSolutions LLC

Position - Company  
President and Scientific Director - InTouch BioSolutions LLC Aug 2008 - Present
Degree - University  
Ph.D., Microbiology, Immunology and Molecular Genetics - University of California, Los Angeles

Under the mentorship of Dr. Sherie L. Morrison.

Show details
2001 - 2004
BS, Microbiology and Molecular Genetics - University of California, Los Angeles 1997 - 1999
Publication Info
A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors. Penichet ML, Dela Cruz JS, Shin SU, Morrison SL Hum Antibodies : 10 : 43-9 : Pending Publication Date
Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity. Dela Cruz JS, Trinh KR, Morrison SL, Penichet ML J Immunol : 165 : 5112-21 : November 1, 2000
A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity. Penichet ML, Dela Cruz JS, Challita-Eid PM, Rosenblatt JD, Morrison SL Cancer Immunol Immunother : 49 : 649-62 : February 1, 2001
Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3). Peng LS, Penichet ML, Dela Cruz JS, Sampogna SL, Morrison SL J Interferon Cytokine Res : 21 : 709-20 : September 1, 2001
An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Ng PP, Dela Cruz JS, Sorour DN, Stinebaugh JM, Shin SU, Shin DS, Morrison SL, Penichet ML Proc Natl Acad Sci U S A : 99 : 10706-11 : August 6, 2002
Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Dela Cruz JS, Lau SY, Ramirez EM, De Giovanni C, Forni G, Morrison SL, Penichet ML Vaccine : 21 : 1317-26 : March 28, 2003
Antibody-cytokine fusion proteins: innovative weapons in the war against cancer. Dela Cruz JS, Huang TH, Penichet ML, Morrison SL Clin Exp Med : 4 : 57-64 : October 1, 2004
Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Dela Cruz JS, Morrison SL, Penichet ML Vaccine : 23 : 4793-803 : September 15, 2005
Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML Vaccine : 24 : 304-16 : January 16, 2006
Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Dela Cruz JS, Trinh KR, Chen HW, Ribas A, Morrison SL, Penichet ML Mol Immunol : 43 : 667-76 : February 1, 2006
Rating  
From david kolb on May 09, 2016 Jay was great - really made sure he understood the work and goals. Very responsive. I would highl... Read more